Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Typ-2-Diabetes und Adipositas Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende

Die Highlights vom Kongress des American College of Cardiology 2024

Im April diskutierten die Herz-Kreislauf-Spezialisten aus der ganzen Welt auf dem  Kongress des American College of Cardiology (ACC) u.a. neue Therapieansätze bei akutem Myokardinfarkt, koronarer Herzerkrankung, kardiogenem Schock oder Aortenklappenstenose. In unserem Kongress-Dossier haben wir für Sie Berichte über die „Late-Breaking Trials“ und andere wichtige Studien zusammengestellt. 
Erweiterte Suche
Anmelden
nach oben
Zeitschrift für Rheumatologie
Erschienen in: Zeitschrift für Rheumatologie 9/2011

01.11.2011 | CME Weiterbildung · Zertifizierte Fortbildung

Psoriasisarthritis – eine bleibende Herausforderung für Rheumatologen und Patienten

Teil 2: Bildgebende Diagnostik, Klassifikation, Therapie

verfasst von: Dr. S. Finzel, M. Englbrecht

Erschienen in: Zeitschrift für Rheumatologie | Ausgabe 9/2011

Einloggen, um Zugang zu erhalten

Zusammenfassung

In den vergangenen Jahren wurde mithilfe einer Vielzahl verschiedener bildgebender Verfahren versucht, den Beginn sowie das Fortschreiten von arthritischen Veränderungen im Rahmen einer Psoriasisarthritis (PsA) zu dokumentieren. Zudem hat sich mit der Entdeckung neuer immunologischer Mechanismen das zur Verfügung stehende Therapierepertoire bei PsA grundlegend verbessert, wodurch sich die Wahrscheinlichkeit einer effektiven Behandlung für die Betroffenen merklich erhöht hat. Trotz eines nach wie vor fehlenden umfassenden Werts zur Angabe der gegenwärtigen Krankheitsaktivität steht inzwischen eine Reihe symptombezogener Instrumente zur Verfügung, um auch den Krankheitsverlauf und den damit verbundenen Behandlungserfolg dokumentieren zu können.
Literatur
1.
Wassenberg S, Fischer-Kahle V, Herborn G, Rau R (2001) A method to score radiographic change in psoriatic arthritis. Z Rheumatol 60(3):156–166PubMed
2.
Gold RH, Bassett LW, Seeger LL (1988) The other arthritides. Roentgenologic features of osteoarthritis, erosive osteoarthritis, ankylosing spondylitis, psoriatic arthritis, Reiter’s disease, multicentric reticulohistiocytosis, and progressive systemic sclerosis. Radiol Clin North Am 26(6):1195–1212PubMed
3.
Resnick D, Broderick TW (1977) Bony proliferation of terminal toe phalanges in psoriasis: the „ivory“ phalanx. J Can Assoc Radiol 28(3):187–189PubMed
4.
Rahman P, Nguyen E, Cheung C et al (2001) Comparison of radiological severity in psoriatic arthritis and rheumatoid arthritis. J Rheumatol 28(5):1041–1044PubMed
5.
Salvarani C, Macchioni P, Cremonesi T et al (1992) The cervical spine in patients with psoriatic arthritis: a clinical, radiological and immunogenetic study. Ann Rheum Dis 51(1):73–77PubMed
6.
Laiho K, Kauppi M (2002) The cervical spine in patients with psoriatic arthritis. Ann Rheum Dis 61(7):650–652PubMed
7.
Gladman DD, Shuckett R, Russell ML et al (1987) Psoriatic arthritis (PSA) – an analysis of 220 patients. Q J Med 62(238):127–141PubMed
8.
Torre Alonso JC, Rodriguez Perez A, Arribas Castrillo JM et al (1991) Psoriatic arthritis (PA): a clinical, immunological and radiological study of 180 patients. Br J Rheumatol 30(4):245–250
9.
Taccari E, Spadaro A, Riccieri V (1996) Correlations between peripheral and axial radiological changes in patients with psoriatic polyarthritis. Rev Rhum Engl Ed 63(1):17–23PubMed
10.
Swen WA, Jacobs JW, Algra PR et al (1999) Sonography and magnetic resonance imaging equivalent for the assessment of full-thickness rotator cuff tears. Arthritis Rheum 42(10):2231–2238PubMed
11.
Wakefield RJ, Gibbon WW, Conaghan PG et al (2000) The value of sonography in the detection of bone erosions in patients with rheumatoid arthritis: a comparison with conventional radiography. Arthritis Rheum 43(12):2762–2770PubMed
12.
D’Agostino MA, Said-Nahal R, Hacquard-Bouder C et al (2003) Assessment of peripheral enthesitis in the spondylarthropathies by ultrasonography combined with power Doppler: a cross-sectional study. Arthritis Rheum 48(2):523–533
13.
De Simone C, Guerriero C, Giampetruzzi AR et al (2003) Achilles tendinitis in psoriasis: clinical and sonographic findings. J Am Acad Dermatol 49(2):217–222
14.
Falsetti P, Frediani B, Fioravanti A et al (2003) Sonographic study of calcaneal entheses in erosive osteoarthritis, nodal osteoarthritis, rheumatoid arthritis and psoriatic arthritis. Scand J Rheumatol 32(4):229–234PubMed
15.
Hu Y, Zhu J, Xue Q et al (2011) Scanning of the sacroiliac joint and entheses by color doppler ultrasonography in patients with ankylosing spondylitis. J Rheumatol 38(8):1651–1655PubMed
16.
Hartung W, Ross CJ, Straub R et al (2010) Ultrasound-guided sacroiliac joint injection in patients with established sacroiliitis: precise IA injection verified by MRI scanning does not predict clinical outcome. Rheumatology (Oxford) 49(8):1479–1482
17.
McQueen FM, Benton N, Crabbe J et al (2001) What is the fate of erosions in early rheumatoid arthritis? Tracking individual lesions using x rays and magnetic resonance imaging over the first two years of disease. Ann Rheum Dis 60(9):859–868PubMed
18.
Antoni C, Dechant C, Hanns-Martin Lorenz PD et al (2002) Open-label study of infliximab treatment for psoriatic arthritis: clinical and magnetic resonance imaging measurements of reduction of inflammation. Arthritis Rheum 47(5):506–512PubMed
19.
Ostergaard M, Peterfy C, Conaghan P et al (2003) OMERACT Rheumatoid Arthritis Magnetic Resonance Imaging Studies. Core set of MRI acquisitions, joint pathology definitions, and the OMERACT RA-MRI scoring system. J Rheumatol 30(6):1385–1386PubMed
20.
Ostergaard M, McQueen F, Wiell C et al (2009) The OMERACT psoriatic arthritis magnetic resonance imaging scoring system (PsAMRIS): definitions of key pathologies, suggested MRI sequences, and preliminary scoring system for PsA Hands. J Rheumatol 36(8):1816–1824PubMed
21.
Grigoryan M, Roemer FW, Mohr A, Genant HK (2004) Imaging in spondyloarthropathies. Curr Rheumatol Rep 6(2):102–109PubMed
22.
Puhakka KB, Jurik AG, Egund N et al (2003) Imaging of sacroiliitis in early seronegative spondylarthropathy. Assessment of abnormalities by MR in comparison with radiography and CT. Acta Radiol 44(2):218–229PubMed
23.
Mehta NN, Yu Y, Saboury B et al (2011) Systemic and vascular inflammation in patients with moderate to severe psoriasis as measured by [18F]-fluorodeoxyglucose positron emission tomography-computed tomography (FDG-PET/CT): a pilot study. Arch Dermatol
24.
Finzel S, Englbrecht M, Engelke K et al (2011) A comparative study of periarticular bone lesions in rheumatoid arthritis and psoriatic arthritis. Ann Rheum Dis 70(1):122–127PubMed
25.
Gladman DD (2008) Mortality in psoriatic arthritis. Clin Exp Rheumatol 26(5 Suppl 51):62–65
26.
Taylor W, Gladman D, Helliwell P et al (2006) Classification criteria for psoriatic arthritis: development of new criteria from a large international study. Arthritis Rheum 54(8):2665–2673PubMed
27.
Congi L, Roussou E (2010) Clinical application of the CASPAR criteria for psoriatic arthritis compared to other existing criteria. Clin Exp Rheumatol 28(3):304–310PubMed
28.
Schnarr S (2006) Arthritis psoriatica. In: Kuipers J, Zeidler H, Köhler L (Hrsg) Medal Rheumatologie. Wiskom, Friedrichshafen, S 58
29.
McGonagle D, Conaghan PG, Emery P (1999) Psoriatic arthritis: a unified concept twenty years on. Arthritis Rheum 42(6):1080–1086PubMed
30.
Moll JM, Wright V (1973) Psoriatic arthritis. Semin Arthritis Rheum 3(1):55–78PubMed
31.
Vasey F, Espinoza L (1984) Psoriatic arthropathy. In: Calin A (Hrsg) Spondyloarthropathies. Grune & Stratton, Orlando, FL, S 151–185
32.
Bennett RM (1979) Psoriatic arthritis. In: McCarty DJ (Hrsg) Arthritis and allied conditions, 9. Aufl. Lea & Febiger, Philadelphia, S 645
33.
Härle P, Hartung W, Lehmann P et al (2010) Detection of psoriasis arthritis with the GEPARD patient questionnaire in a dermatologic outpatient setting. Z Rheumatol 69(2):157–160, 62–63PubMed
34.
Feldman SR, Krueger GG (2005) Psoriasis assessment tools in clinical trials. Ann Rheum Dis 64(Suppl 2):ii65–ii68; discussion ii9–ii73PubMed
35.
Rich P, Scher RK (2003) Nail Psoriasis severity index: a useful tool for evaluation of nail psoriasis. J Am Acad Dermatol 49(2):206–212PubMed
36.
Cassell SE, Bieber JD, Rich P et al (2007) The modified nail psoriasis severity index: validation of an instrument to assess psoriatic nail involvement in patients with psoriatic arthritis. J Rheumatol 34(1):123–129PubMed
37.
Healy PJ, Helliwell PS (2008) Measuring clinical enthesitis in psoriatic arthritis: assessment of existing measures and development of an instrument specific to psoriatic arthritis. Arthritis Rheum 59(5):686–691PubMed
38.
Heuft-Dorenbosch L, Spoorenberg A, Tubergen A van et al (2003) Assessment of enthesitis in ankylosing spondylitis. Ann Rheum Dis 62(2):127–132PubMed
39.
Felson DT, Anderson JJ, Boers M et al (1993) The American College of Rheumatology preliminary core set of disease activity measures for rheumatoid arthritis clinical trials. The committee on outcome measures in rheumatoid arthritis clinical trials. Arthritis Rheum 36(6):729–740PubMed
40.
Helliwell PS, Firth J, Ibrahim GH et al (2005) Development of an assessment tool for dactylitis in patients with psoriatic arthritis. J Rheumatol 32(9):1745–1750PubMed
41.
Jones SD, Porter J, Garrett SL et al (1995) A new scoring system for the Bath Ankylosing Spondylitis Metrology Index (BASMI). J Rheumatol 22(8):1609PubMed
42.
Calin A, Garrett S, Whitelock H et al (1994) A new approach to defining functional ability in ankylosing spondylitis: the development of the Bath Ankylosing Spondylitis Functional Index. J Rheumatol 21(12):2281–2285PubMed
43.
Fries JF, Spitz PW, Young DY (1982) The dimensions of health outcomes: the health assessment questionnaire, disability and pain scales. J Rheumatol 9(5):789–793PubMed
44.
Chandran V, Bhella S, Schentag C, Gladman DD (2007) Functional assessment of chronic illness therapy-fatigue scale is valid in patients with psoriatic arthritis. Ann Rheum Dis 66(7):936–939PubMed
45.
Garrett S, Jenkinson T, Kennedy LG et al (1994) A new approach to defining disease status in ankylosing spondylitis: the Bath Ankylosing Spondylitis Disease Activity Index. J Rheumatol 21(12):2286–2291PubMed
46.
Englbrecht M, Wang Y, Ronneberger M et al (2010) Measuring joint involvement in polyarticular psoriatic arthritis: an introduction of alternatives. Arthritis Care Res (Hoboken) 62(7):977–983
47.
Khan M, Schentag C, Gladman DD (2003) Clinical and radiological changes during psoriatic arthritis disease progression. J Rheumatol 30(5):1022–1026PubMed
48.
Radtke MA, Reich K, Blome C et al (2009) Prevalence and clinical features of psoriatic arthritis and joint complaints in 2009 patients with psoriasis: results of a German national survey. J Eur Acad Dermatol Venereol 23(6):683–691PubMed
49.
Christophers E, Barker JN, Griffiths CE et al (2010) The risk of psoriatic arthritis remains constant following initial diagnosis of psoriasis among patients seen in European dermatology clinics. J Eur Acad Dermatol Venereol 24(5):548–554PubMed
50.
Love TJ, Gudjonsson JE, Valdimarsson H, Gudbjornsson B (2010) Small joint involvement in psoriatic arthritis is associated with onycholysis: the Reykjavik Psoriatic Arthritis Study. Scand J Rheumatol 39(4):299–302PubMed
51.
Williamson L, Dalbeth N, Dockerty JL et al (2004) Extended report: nail disease in psoriatic arthritis – clinically important, potentially treatable and often overlooked. Rheumatology (Oxford) 43(6):790–794
52.
McGonagle D (2009) Enthesitis: an autoinflammatory lesion linking nail and joint involvement in psoriatic disease. J Eur Acad Dermatol Venereol 23(Suppl 1):9–13PubMed
53.
Gladman DD, Stafford-Brady F, Chang CH et al (1990) Longitudinal study of clinical and radiological progression in psoriatic arthritis. J Rheumatol 17(6):809–812PubMed
54.
Kane D, Stafford L, Bresnihan B, FitzGerald O (2003) A prospective, clinical and radiological study of early psoriatic arthritis: an early synovitis clinic experience. Rheumatology (Oxford) 42(12):1460–1468
55.
Gladman DD (1994) Natural history of psoriatic arthritis. Baillieres Clin Rheumatol 8(2):379–394PubMed
56.
Gladman DD, Farewell VT, Wong K, Husted J (1998) Mortality studies in psoriatic arthritis: results from a single outpatient center. II. Prognostic indicators for death. Arthritis Rheum 41(6):1103–1110PubMed
57.
Bond SJ, Farewell VT, Schentag CT, Gladman DD (2007) Predictors for radiological damage in psoriatic arthritis: results from a single centre. Ann Rheum Dis 66(3):370–376PubMed
58.
Husted JA, Tom BD, Farewell VT et al (2005) Description and prediction of physical functional disability in psoriatic arthritis: a longitudinal analysis using a Markov model approach. Arthritis Rheum 53(3):404–409PubMed
59.
Gladman DD, Farewell VT, Kopciuk KA, Cook RJ (1998) HLA markers and progression in psoriatic arthritis. J Rheumatol 25(4):730–733PubMed
60.
Gladman DD, Farewell VT (1999) Progression in psoriatic arthritis: role of time varying clinical indicators. J Rheumatol 26(11):2409–2413PubMed
61.
Gladman DD, Farewell VT, Nadeau C (1995) Clinical indicators of progression in psoriatic arthritis: multivariate relative risk model. J Rheumatol 22(4):675–679PubMed
62.
Queiro-Silva R, Torre-Alonso JC, Tinture-Eguren T, Lopez-Lagunas I (2003) A polyarticular onset predicts erosive and deforming disease in psoriatic arthritis. Ann Rheum Dis 62(1):68–70PubMed
63.
Bakker MF, Jacobs JW, Verstappen SM, Bijlsma JW (2007) Tight control in the treatment of rheumatoid arthritis: efficacy and feasibility. Ann Rheum Dis 66(Suppl 3):iii56–iii60PubMed
64.
Vlam K de, Lories RJ (2008) Remission in psoriatic arthritis. Curr Rheumatol Rep 10(4):297–302PubMed
65.
Ritchlin CT, Kavanaugh A, Gladman DD et al (2009) Treatment recommendations for psoriatic arthritis. Ann Rheum Dis 68(9):1387–1394PubMed
66.
Kavanaugh AF, Ritchlin CT (2006) Systematic review of treatments for psoriatic arthritis: an evidence based approach and basis for treatment guidelines. J Rheumatol 33(7):1417–1421PubMed
67.
Soriano ER, McHugh NJ (2006) Therapies for peripheral joint disease in psoriatic arthritis. A systematic review. J Rheumatol 33(7):1422–1430PubMed
68.
Nash P (2006) Therapies for axial disease in psoriatic arthritis. A systematic review. J Rheumatol 33(7):1431–1434PubMed
69.
Ritchlin CT (2006) Therapies for psoriatic enthesopathy. A systematic review. J Rheumatol 33(7):1435–1438PubMed
70.
Strober BE, Siu K, Menon K (2006) Conventional systemic agents for psoriasis. A systematic review. J Rheumatol 33(7):1442–1446PubMed
71.
Boehncke WH, Prinz J, Gottlieb AB (2006) Biologic therapies for psoriasis. A systematic review. J Rheumatol 33(7):1447–1451PubMed
72.
Cassell S, Kavanaugh AF (2006) Therapies for psoriatic nail disease. A systematic review. J Rheumatol 33(7):1452–1456PubMed
73.
Coates LC, Fransen J, Helliwell PS (2010) Defining minimal disease activity in psoriatic arthritis: a proposed objective target for treatment. Ann Rheum Dis 69(1):48–53PubMed
74.
Coates LC, Cook R, Lee KA et al (2010) Frequency, predictors, and prognosis of sustained minimal disease activity in an observational psoriatic arthritis cohort. Arthritis Care Res (Hoboken) 62(7):970–976
75.
Coates LC, Helliwell PS (2010) Validation of minimal disease activity criteria for psoriatic arthritis using interventional trial data. Arthritis Care Res (Hoboken) 62(7):965–969
76.
Sarzi-Puttini P, Santandrea S, Boccassini L et al (2001) The role of NSAIDs in psoriatic arthritis: evidence from a controlled study with nimesulide. Clin Exp Rheumatol 19(1 Suppl 22):17–20
77.
Clark DW, Coulter DM (2003) Psoriasis associated with rofecoxib. Arch Dermatol 139(9):1223PubMed
78.
Nash P, Clegg DO (2005) Psoriatic arthritis therapy: NSAIDs and traditional DMARDs. Ann Rheum Dis 64(Suppl 2):ii74–ii77PubMed
79.
Mease PJ (2009) Psoriatic arthritis assessment and treatment update. Curr Opin Rheumatol 21(4):348–355PubMed
80.
Black RL, O’Brien WM, Vanscott EJ et al (1964) Methotrexate therapy in psoriatic arthritis; double-blind study on 21 patients. JAMA 189:743–747PubMed
81.
Abu-Shakra M, Gladman DD, Thorne JC et al (1995) Longterm methotrexate therapy in psoriatic arthritis: clinical and radiological outcome. J Rheumatol 22(2):241–245PubMed
82.
St Clair EW (2002) Infliximab treatment for rheumatic disease: clinical and radiological efficacy. Ann Rheum Dis 61(Suppl 2):ii67–ii69
83.
Combe B, Goupille P, Kuntz JL et al (1996) Sulphasalazine in psoriatic arthritis: a randomized, multicentre, placebo-controlled study. Br J Rheumatol 35(7):664–668PubMed
84.
Rahman P, Gladman DD, Cook RJ et al (1998) The use of sulfasalazine in psoriatic arthritis: a clinic experience. J Rheumatol 25(10):1957–1961PubMed
85.
Clegg DO, Reda DJ, Mejias E et al (1996) Comparison of sulfasalazine and placebo in the treatment of psoriatic arthritis. A Department of Veterans Affairs Cooperative Study. Arthritis Rheum 39(12):2013–2020PubMed
86.
Farr M, Kitas GD, Waterhouse L et al (1990) Sulphasalazine in psoriatic arthritis: a double-blind placebo-controlled study. Br J Rheumatol 29(1):46–49PubMed
87.
Gupta AK, Grober JS, Hamilton TA et al (1995) Sulfasalazine therapy for psoriatic arthritis: a double blind, placebo controlled trial. J Rheumatol 22(5):894–898PubMed
88.
Clegg DO, Reda DJ, Abdellatif M (1999) Comparison of sulfasalazine and placebo for the treatment of axial and peripheral articular manifestations of the seronegative spondylarthropathies: a Department of Veterans Affairs cooperative study. Arthritis Rheum 42(11):2325–2329PubMed
89.
Fraser SM, Hopkins R, Hunter JA et al (1993) Sulphasalazine in the management of psoriatic arthritis. Br J Rheumatol 32(10):923–925PubMed
90.
Dougados M, Linden S vam der, Leirisalo-Repo M et al (1995) Sulfasalazine in the treatment of spondylarthropathy. A randomized, multicenter, double-blind, placebo-controlled study. Arthritis Rheum 38(5):618–627PubMed
91.
Fox RI (1998) Mechanism of action of leflunomide in rheumatoid arthritis. J Rheumatol Suppl 53:20–26PubMed
92.
Liang GC, Barr WG (2001) Open trial of leflunomide for refractory psoriasis and psoriatic arthritis. J Clin Rheumatol 7(6):366–370PubMed
93.
Kaltwasser JP, Nash P, Gladman D et al (2004) Efficacy and safety of leflunomide in the treatment of psoriatic arthritis and psoriasis: a multinational, double-blind, randomized, placebo-controlled clinical trial. Arthritis Rheum 50(6):1939–1950PubMed
94.
Steinsson K, Jonsdottir I, Valdimarsson H (1990) Cyclosporin A in psoriatic arthritis: an open study. Ann Rheum Dis 49(8):603–606PubMed
95.
Spadaro A, Riccieri V, Sili-Scavalli A et al (1995) Comparison of cyclosporin A and methotrexate in the treatment of psoriatic arthritis: a one-year prospective study. Clin Exp Rheumatol 13(5):589–593PubMed
96.
Mazzanti G, Coloni L, De Sabbata G, Paladini G (1994) Methotrexate and cyclosporin combined therapy in severe psoriatic arthritis. A pilot study. Acta Derm Venereol Suppl (Stockh) 186:116–117
97.
Gladman DD, Blake R, Brubacher B, Farewell VT (1992) Chloroquine therapy in psoriatic arthritis. J Rheumatol 19(11):1724–1726PubMed
98.
Lipsky JJ (1996) Mycophenolate mofetil. Lancet 348(9038):1357–1359PubMed
99.
Grundmann-Kollmann M, Mooser G, Schraeder P et al (2000) Treatment of chronic plaque-stage psoriasis and psoriatic arthritis with mycophenolate mofetil. J Am Acad Dermatol 42(5 Pt 1):835–837PubMed
100.
Baum J, Hurd E, Lewis D et al (1973) Treatment of psoriatic arthritis with 6-mercaptopurine. Arthritis Rheum 16(2):139–147PubMed
101.
Wahba A, Cohen H (1980) Therapeutic trials with oral colchicine in psoriasis. Acta Derm Venereol 60(6):515–520PubMed
102.
Seideman P, Fjellner B, Johannesson A (1987) Psoriatic arthritis treated with oral colchicine. J Rheumatol 14(4):777–779PubMed
103.
Price R, Gibson T (1986) D-penicillamine and psoriatic arthropathy. Br J Rheumatol 25(2):228PubMed
104.
Jung N, Hellmann M, Hoheisel R et al (2010) An open-label pilot study of the efficacy and safety of anakinra in patients with psoriatic arthritis refractory to or intolerant of methotrexate (MTX). Clin Rheumatol 29(10):1169–1173PubMed
105.
Sterry W, Ortonne JP, Kirkham B et al (2010) Comparison of two etanercept regimens for treatment of psoriasis and psoriatic arthritis: PRESTA randomised double blind multicentre trial. BMJ 340:c147PubMed
106.
Antoni C, Krueger GG, Vlam K de et al (2005) Infliximab improves signs and symptoms of psoriatic arthritis: results of the IMPACT 2 trial. Ann Rheum Dis 64(8):1150–1157PubMed
107.
Mease PJ, Gladman DD, Ritchlin CT et al (2005) Adalimumab for the treatment of patients with moderately to severely active psoriatic arthritis: results of a double-blind, randomized, placebo-controlled trial. Arthritis Rheum 52(10):3279–3289PubMed
108.
Kavanaugh A, McInnes I, Mease P et al (2009) Golimumab, a new human tumor necrosis factor alpha antibody, administered every four weeks as a subcutaneous injection in psoriatic arthritis: twenty-four-week efficacy and safety results of a randomized, placebo-controlled study. Arthritis Rheum 60(4):976–986PubMed
Metadaten
Titel
Psoriasisarthritis – eine bleibende Herausforderung für Rheumatologen und Patienten
Teil 2: Bildgebende Diagnostik, Klassifikation, Therapie
verfasst von
Dr. S. Finzel
M. Englbrecht
Publikationsdatum
01.11.2011
Verlag
Springer-Verlag
Erschienen in
Zeitschrift für Rheumatologie / Ausgabe 9/2011
Print ISSN: 0340-1855
Elektronische ISSN: 1435-1250
DOI
https://doi.org/10.1007/s00393-011-0870-y

Weitere Artikel der Ausgabe 9/2011

Zeitschrift für Rheumatologie 9/2011 Zur Ausgabe

Originalien

Medikamentöse Osteoporoseprophylaxe und -therapie bei Patienten mit rheumatoider Arthritis (ORA-Studie)

Mitteilungen der DRL

Mitteilungen der DRL

Leitthema

Angeborene und endogene endokrine Myopathien

Mitteilungen der DGRh

Mitteilungen der DGRh

Neues aus der Forschung

Darmflora als Regulator des Immunsystems

Leitthema

Nebenschilddrüse und rheumatologische Manifestationen

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

Blutdrucksenkung könnte Uterusmyome verhindern

21.05.2024 Krebsvorsorge in der Gynäkologie Nachrichten

Frauen mit unbehandelter oder neu auftretender Hypertonie haben ein deutlich erhöhtes Risiko für Uterusmyome. Eine Therapie mit Antihypertensiva geht hingegen mit einer verringerten Inzidenz der gutartigen Tumoren einher.

„Jeder Fall von plötzlichem Tod muss obduziert werden!“

17.05.2024 Plötzlicher Herztod Nachrichten

Ein signifikanter Anteil der Fälle von plötzlichem Herztod ist genetisch bedingt. Um ihre Verwandten vor diesem Schicksal zu bewahren, sollten jüngere Personen, die plötzlich unerwartet versterben, ausnahmslos einer Autopsie unterzogen werden.

Hirnblutung unter DOAK und VKA ähnlich bedrohlich

17.05.2024 Direkte orale Antikoagulanzien Nachrichten

Kommt es zu einer nichttraumatischen Hirnblutung, spielt es keine große Rolle, ob die Betroffenen zuvor direkt wirksame orale Antikoagulanzien oder Marcumar bekommen haben: Die Prognose ist ähnlich schlecht.

Schlechtere Vorhofflimmern-Prognose bei kleinem linken Ventrikel

17.05.2024 Vorhofflimmern Nachrichten

Nicht nur ein vergrößerter, sondern auch ein kleiner linker Ventrikel ist bei Vorhofflimmern mit einer erhöhten Komplikationsrate assoziiert. Der Zusammenhang besteht nach Daten aus China unabhängig von anderen Risikofaktoren.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen
Bildnachweise